At the time of writing, Halozyme Therapeutics Inc [HALO] stock is trading at $59.05, up 2.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The HALO shares have gain 2.62% over the last week, with a monthly amount glided 13.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Equal-Weight on May 14, 2025, and kept the price target unchanged to $62. On May 13, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $47 on the stock. Wells Fargo downgraded its rating to a Equal Weight and increased its price target to $62 on October 07, 2024. JP Morgan downgraded its rating to a Neutral and raised its price target to $57 on September 19, 2024. Piper Sandler downgraded its rating to Neutral for this stock on June 07, 2024, and upped its price target to $51. In a note dated February 29, 2024, TD Cowen initiated an Outperform rating and provided a target price of $54 on this stock.
For the past year, the stock price of Halozyme Therapeutics Inc fluctuated between $42.01 and $70.50. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $59.05 at the most recent close of the market. An investor can expect a potential return of 5.0% based on the average HALO price forecast.
Analyzing the HALO fundamentals
According to Halozyme Therapeutics Inc [NASDAQ:HALO], the company’s sales were 1.08B for trailing twelve months, which represents an 35.22% jump. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.55%, Pretax Profit Margin comes in at 0.56%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.22 and Total Capital is 0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 57.99 points at the first support level, and at 56.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 59.80, and for the 2nd resistance point, it is at 60.55.
Ratios To Look Out For
It is important to note that Halozyme Therapeutics Inc [NASDAQ:HALO] has a current ratio of 8.39. On the other hand, the Quick Ratio is 7.30, and the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 6.71, the price to book ratio is 15.08 and price to earnings (TTM) ratio is 15.67.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Jul 10 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Jul 09 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Jul 08 ’25.
